From: In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions
SN
GI absorption
BBB permeant
Bioavailability score
CYP-substrate/inhibitor
5
Low
No
0.55
3A4
1A2
2C19
2C9
2D6
9
Yes
10
11
Vem.